Table 1

Summary of mechanical circulatory support (MCS) device trials

YearnStudy informationDesignPrimary end pointResults
IABP-SHOCK II12012600IABP vs MT
AMI with CS and revascularisation
Multicentre
RCT
30-day mortalityNo difference in mortality
(39.7% IABP vs 41.3% MT)
Thiele H et al31200541TH vs IABP
AMI with CS
Single centre
RCT
Cardiac Power Index and haemodynamicsTH improved haemodynamics
2◦ end point 30-day mortality: no difference (TH 43% vs IABP 45%)
TandemHeart Investigators Group32200642TH vs IABP
Within 24 hours of CS
70% AMI, 30% HF
Multicenter RCTHaemodynamics
CI, MAP, PCWP
TH improved haemodynamics
2◦ end point 30 day mortality: no difference (TH 47% vs IABP 36%)
ISAR-Shock33200826Impella 2.5 vs IABP
AMI with CS
Multicentre
RCT
Change in Cardiac Index from baseline to 30 minImpella 2.5 improved haemodynamics
2◦ end point 30-day mortality: no difference (46% both groups)
IMPRESS in severe shock34201648Impella CP vs IABP
AMI with STEMI and CS
Multicentre RCT30-day mortalityNo difference in 30-day mortality
(50% CP vs 46% IABP)
National Cardiogenic Shock Initiative (NCSI)35
(NCT03677180)
Recruiting500Early initiation of MCSMulticentre cohortSurvival to hospital dischargeOngoing study
ECMO-CS36 (NCT02301819)Recruiting120VA-ECMO
CS
Multicentre
RCT
30-day mortality, cardiac arrest and additional MCSOngoing study
Danish CS Trial (DanShock) (NCT01633502)Ongoing360Impella CP vs IABP
AMI with STEMI and CS
Multicentre
RCT
6-month mortalityOngoing study
REVERSE Trial (NCT03431467)Recruiting96Impella CP with VA-ECMO
CS
Single-centre
RCT
30-day recoveryOngoing study
  • AMI, acute myocardial infarction;CS, cardiogenic shock;HF, heart failure; IABP, intraoartic balloon pump;MAP, mean arterial pressure;MT, medical therapy; PCWP, pulmonary capillary wedge pressure; RCT, randomised control trial;SHOCK, SHould we emergently revascularise Occluded Coronaries for cardiogenic shocK; TH, Tandem Heart;VA-ECMO, venoarterial extracorporeal membrane oxygenation.